TCM
HRMY icon

Tributary Capital Management’s Harmony Biosciences HRMY Stock Holding History

Tributary Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-206,218
Closed -$7.26M – 166
2023
Q2 		$7.26M Sell
206,218
-3,725
-2% -$129K 0.65% 66
2023
Q1 		$6.85M Buy
209,943
+81,518
+63% +$3.71M 0.64% 66
2022
Q4 		$7.08M Buy
+128,425
New +$7.06M 0.71% 65

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Tributary Capital Management's HRMY Position: Q3 2023 in Review

Tributary Capital Management sold out of Harmony Biosciences (HRMY) in Q3 2023, closing a stake of 206,218 shares — an estimated $7.26M sold.

Tributary Capital Management first reported a position in HRMY in Q4 2022 and held it in 3 quarters. The position peaked at $7.26M in Q2 2023. 204 funds tracked by Wall St. Rank hold HRMY as of Q3 2023.

  • Tributary Capital Management reported no remaining Harmony Biosciences position as of Q3 2023 after selling out during the quarter.
  • Tributary Capital Management sold 206,218 Harmony Biosciences shares in Q3 2023, an estimated $7.26M.
  • Tributary Capital Management first reported a position in Harmony Biosciences in Q4 2022 and held it in 3 quarters.
  • Tributary Capital Management's Harmony Biosciences position peaked at $7.26M in Q2 2023.
  • 204 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2023.

Based on Tributary Capital Management's 13F filing for Q3 2023, filed 11 Oct 2023.